- Home
- NWG vs REGN Comparison
NWG vs REGN Comparison
Compare NWG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWG
- REGN
- Stock Information
- Founded
- NWG 1727
- REGN 1988
- Country
- NWG United Kingdom
- REGN United States
- Employees
- NWG N/A
- REGN N/A
- Industry
- NWG Commercial Banks
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NWG Finance
- REGN Health Care
- Exchange
- NWG Nasdaq
- REGN Nasdaq
- Market Cap
- NWG 59.2B
- REGN 59.5B
- IPO Year
- NWG N/A
- REGN 1991
- Fundamental
- Price
- NWG $14.49
- REGN $579.75
- Analyst Decision
- NWG Strong Buy
- REGN Buy
- Analyst Count
- NWG 1
- REGN 23
- Target Price
- NWG N/A
- REGN $794.83
- AVG Volume (30 Days)
- NWG 2.8M
- REGN 1.1M
- Earning Date
- NWG 10-24-2025
- REGN 10-28-2025
- Dividend Yield
- NWG 4.38%
- REGN 0.60%
- EPS Growth
- NWG 25.48
- REGN 5.03
- EPS
- NWG 0.82
- REGN 39.67
- Revenue
- NWG $20,360,323,334.00
- REGN $14,214,200,000.00
- Revenue This Year
- NWG $15.92
- REGN N/A
- Revenue Next Year
- NWG $6.44
- REGN $4.74
- P/E Ratio
- NWG $17.71
- REGN $14.70
- Revenue Growth
- NWG 8.06
- REGN 5.38
- 52 Week Low
- NWG $9.16
- REGN $476.49
- 52 Week High
- NWG $15.52
- REGN $1,024.36
- Technical
- Relative Strength Index (RSI)
- NWG 53.31
- REGN 51.47
- Support Level
- NWG $14.18
- REGN $555.00
- Resistance Level
- NWG $14.92
- REGN $618.01
- Average True Range (ATR)
- NWG 0.16
- REGN 17.21
- MACD
- NWG 0.08
- REGN 1.08
- Stochastic Oscillator
- NWG 68.85
- REGN 46.08
About NWG NatWest Group plc (each representing two (2))
NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the UK, offering clients lending and payment services as well as asset management services.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).